J 2011

Cognitive effects of long-term treatment with waking-hour subcutaneous apomorphine infusions in patients with advanced Parkinson's disease

KUBÍKOVÁ, Radka, Mojmír TYRLÍK and Irena REKTOROVÁ

Basic information

Original name

Cognitive effects of long-term treatment with waking-hour subcutaneous apomorphine infusions in patients with advanced Parkinson's disease

Authors

KUBÍKOVÁ, Radka (203 Czech Republic, belonging to the institution), Mojmír TYRLÍK (203 Czech Republic, belonging to the institution) and Irena REKTOROVÁ (203 Czech Republic, guarantor, belonging to the institution)

Edition

Ceska a Slovenska Neurologie a Neurochirurgie, Czech Medical Association J.E. Purkyne, 2011, 1210-7859

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30000 3. Medical and Health Sciences

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 0.279

RIV identification code

RIV/00216224:14740/11:00060542

Organization unit

Central European Institute of Technology

UT WoS

000294035900009

Keywords in English

Affective; Apomorphine; Cognitive; Dementia; Parkinson's disease

Tags

Tags

International impact, Reviewed
Změněno: 23/4/2013 07:30, Olga Křížová

Abstract

V originále

Aims: To determine whether long-term treatment with continuous subcutaneous apomorphine infusions (CSAI) is safe for patients with Parkinson's disease (PD) with a history of hallucinations and/or marked cognitive deficit. Methods: 12 PD patients (9 men, 3 women; age 71.8 +- 6 years) were given neuropsychological assessment prior to continuous administration of CSAI and fourteen months after it. Results: CSAI led to clinical improvement, at least minimal, in all subjects. However, the treatment led to statistically significant impairment in verbal fluency tasks, the Mattis dementia rating scale (MDRS) score and the attention and initiation subtests. No mood changes were detected. Conclusions: We observed significant impairment in "frontal-like" tasks after continuous treatment with CSAI in our PD patients with baseline cognitive impairment. Further longitudinal controlled studies are needed to assess the impact of both CSAI and PD progression. We suggest cautious selection of patients eligible for CSAI therapy with respect to their cognitive profiles and/or neuropsychiatric complications.

Links

ED1.1.00/02.0068, research and development project
Name: CEITEC - central european institute of technology
MSM0021622404, plan (intention)
Name: Vnitřní organizace a neurobiologické mechanismy funkčních systémů CNS
Investor: Ministry of Education, Youth and Sports of the CR, The internal organisation and neurobiological mechanisms of functional CNS systems under normal and pathological conditions.

Files attached

Rektorova_CSNN_2011-ApoGo.pdf
Request the author's version of the file